ENBI — Entheon Biomedical Balance Sheet
0.000.00%
Last trade - 00:00- CA$1.66m
- CA$1.14m
- 31
- 15
- 30
- 14
Annual balance sheet for Entheon Biomedical, fiscal year end - November 30th, CAD millions except per share, conversion factor applied.
2020 March 31st | 2021 November 30th | 2022 November 30th | 2023 November 30th | 2024 November 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 1.13 | 2.05 | 0.68 | 0.345 | 0.136 |
| Net Total Receivables | 0.012 | 0.028 | 0.042 | 0.006 | 0.004 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 1.16 | 3.21 | 0.744 | 0.396 | 0.18 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.564 | 0.164 | 0 | — | — |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 1.72 | 9.98 | 0.769 | 0.401 | 0.185 |
| Payable / Accrued | |||||
| Notes Payable / Short Term Debt | |||||
| Total Current Liabilities | 0.028 | 0.928 | 0.155 | 0.085 | 0.04 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 0.028 | 0.928 | 0.155 | 0.085 | 0.04 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 1.69 | 9.05 | 0.615 | 0.316 | 0.145 |
| Total Liabilities & Shareholders' Equity | 1.72 | 9.98 | 0.769 | 0.401 | 0.185 |
| Total Common Shares Outstanding |